MO logo

Altria Group, Inc. Stock Price

NYSE:MO Community·US$120.4b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 435 Fair Values set on narratives written by author

MO Share Price Performance

US$0
-59.61 (-100.00%)
US$70.36
Fair Value
US$0
-59.61 (-100.00%)
Price US$0

MO Community Narratives

·
Fair Value US$70.36 3.7% overvalued intrinsic discount

Dividend Momentum And Regulatory Clarity Will Drive Further Gains Through 2025

3users have liked this narrative
0users have commented on this narrative
224users have followed this narrative
·
Fair Value US$59 23.7% overvalued intrinsic discount

Illicit E-Vapor Surge Will Jeopardize Smoke-Free Prospects

0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
·
Fair Value US$70.98 2.8% overvalued intrinsic discount

Smoke-free Expansion Will Reshape US Nicotine Market Despite Risks

0users have liked this narrative
0users have commented on this narrative
17users have followed this narrative
US$70.36
3.7% overvalued intrinsic discount
Revenue
0.86% p.a.
Profit Margin
46.2%
Future PE
15.01x
Price in 2029
US$88.4
US$59
23.7% overvalued intrinsic discount
Revenue
0.58% p.a.
Profit Margin
45.89%
Future PE
12.8x
Price in 2029
US$74.22
US$70.98
2.8% overvalued intrinsic discount
Revenue
0.75% p.a.
Profit Margin
44.16%
Future PE
15.19x
Price in 2028
US$86.96

Trending Discussion

No trending discussion available.

Updated Narratives

MO logo

MO: Smoke Free Shift And FDA Guidance Will Shape Future Returns

Fair Value: US$70.36 3.7% overvalued intrinsic discount
224 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
MO logo

MO: Future Returns Will Hinge On FDA Nicotine Product Decisions

Fair Value: US$59 23.7% overvalued intrinsic discount
9 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
MO logo

Smoke-free Expansion Will Reshape US Nicotine Market Despite Risks

Fair Value: US$70.98 2.8% overvalued intrinsic discount
17 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

6 star dividend payer and good value.

2 Risks
3 Rewards

Altria Group, Inc. Key Details

US$20.4b

Revenue

US$2.6b

Cost of Revenue

US$17.8b

Gross Profit

US$9.8b

Other Expenses

US$8.0b

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Jul 30, 2026
4.81
87.38%
39.42%
-778.3%
View Full Analysis

About MO

Founded
1822
Employees
5900
CEO
Salvatore Mancuso
WebsiteView website
www.altria.com

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. It offers cigarettes primarily under the Marlboro brand; large cigars and pipe tobacco under the Black & Mild brand; moist smokeless tobacco and oral tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands; oral nicotine pouches under the on! brand; and e-vapor products under the NJOY ACE brand. The company sells its products to distributors, as well as large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Recent MO News & Updates

Seeking Alpha Jul 21

Altria: Why The 30% Premium Is Too Much

Summary Altria Group, Inc. is rated Sell due to a 30% premium to its historical P/E, despite stagnant results and uncertain smoke-free growth. MO's Q1 outperformed the industry in smokeables, but oral tobacco remains challenged, with on! Growing shipments yet losing share amid intense competition. Management reaffirmed 2026 EPS guidance ($5.56–$5.72) but expressed caution given macro uncertainty and lack of conviction in near-term margin expansion. MO's high gross margins and cash flow support dividends, but secular decline in cigarettes and unclear oral tobacco prospects limit long-term appeal. Read the full article on Seeking Alpha
Narrative Update Jun 29

MO: Smoke Free Shift And FDA Guidance Will Shape Future Returns

Altria Group's analyst fair value estimate has shifted from $65.50 to about $70.36. This change reflects recent price target increases across several firms as analysts point to potential next-generation product growth following updated FDA guidance.

Recent updates

No updates